Redefining Precision Oncology, One Alteration at a Time

About Alterome: A precision-oncology company designing small-molecule cancer therapies to hit specific disease-driving mutations while sparing the closely related biology healthy cells need.

Precision oncology has carried a hidden compromise

For years, the practical way to block a cancer pathway was often to inhibit a whole family of proteins. That bargain made sense. Protein structures can be difficult to drug, and medicinal chemists worked with the binding sites available to them.

But the same proteins that help tumors grow may also regulate essential functions in healthy tissue. AKT is a good example. Older approaches have generally inhibited several forms of AKT at once. That can suppress cancer signaling, but it can also interfere with normal metabolism and other processes, narrowing the margin between an effective dose and an intolerable one.

KRAS presents a different version of the problem. It was long considered undruggable because its shape offered few obvious places for a small molecule to bind. The first mutation-specific medicines proved KRAS could be reached. They also exposed the next challenge: covering more mutations and protein states without unnecessarily inhibiting related proteins.

From a genetic address to a molecule that fits

Alterome brings those disciplines together. Rather than searching broadly for unproven biology, the team starts with clinically validated cancer drivers and asks whether a more carefully designed molecule can change the therapeutic tradeoff.

Its two lead programs make that strategy concrete. Tanerasertib, also called ALTA2618, is designed to target the AKT1 E17K mutation while sparing wild-type AKT1 and avoiding inhibition of AKT2. ALTA3263 is designed to inhibit a broad range of KRAS mutations in both the protein's ON and OFF states, while sparing the related proteins HRAS and NRAS. Both programs are in Phase 1/1b studies evaluating safety, tolerability, pharmacokinetics, and preliminary activity.

The difference is not novelty for its own sake

What makes Alterome distinctive is the sequence of its thinking. It begins with biology whose importance is already clear, then applies precision to the part that has constrained treatment: the drug itself.

That choice reduces one kind of uncertainty while taking on a hard engineering problem: understand the mutant protein, bind the intended form, spare related biology, and preserve the properties required for an oral medicine. In four years, Alterome moved two internally discovered candidates from idea to clinical testing. That is not evidence of efficacy, but it shows the company's integrated approach can produce candidates ready to be tested in people.

Why this matters beyond the laboratory

For a patient, precision is not a scientific adjective. It shapes whether a medicine can be dosed strongly enough, tolerated long enough, and used across the mutations that appear in cancer. The difference between hitting a protein family and the disease-driving alteration can separate a promising mechanism from a practical treatment.

The real question

The question Alterome is asking is not simply whether KRAS or AKT can be inhibited. It is whether drug design can become precise enough to separate the biology that drives cancer from the biology a person needs to live.

If Alterome succeeds, the larger shift will be that precision oncology moved one level deeper, from identifying the genetic address of a cancer to designing medicines that fit it with less compromise. That is the future we saw in the company: known targets no longer accepted as unreachable, and greater precision widening what treatment can make possible.